Literature DB >> 21263451

Continuous re-evaluation in differentiated thyroid carcinoma.

Frederik A Verburg, Christoph Reiners.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21263451     DOI： 10.1038/nrendo.2011.11

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  9 in total

1.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

Review 2.  Medical management of thyroid cancer: a risk adapted approach.

Authors:  R Michael Tuttle; Rebecca Leboeuf; Ashok R Shaha
Journal:  J Surg Oncol       Date:  2008-06-15       Impact factor: 3.454

3.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

4.  Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients.

Authors:  Frederik A Verburg; Bart de Keizer; Cornelis J M Lips; Pierre M J Zelissen; John M H de Klerk
Journal:  Eur J Endocrinol       Date:  2005-01       Impact factor: 6.664

5.  The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients.

Authors:  Frederik A Verburg; Michael Lassmann; Uwe Mäder; Markus Luster; Christoph Reiners; Heribert Hänscheid
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

6.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

7.  No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.

Authors:  Frederik Anton Verburg; Marcel P M Stokkel; Christian Düren; Robbert B T Verkooijen; Uwe Mäder; Johannes W van Isselt; Robert J Marlowe; Johannes W Smit; Christoph Reiners; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-29       Impact factor: 9.236

8.  A comparison of prognostic classification systems for differentiated thyroid carcinoma.

Authors:  Frederik A Verburg; Uwe Mäder; Cas L J J Kruitwagen; Markus Luster; Christoph Reiners
Journal:  Clin Endocrinol (Oxf)       Date:  2009-10-31       Impact factor: 3.478

9.  Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.

Authors:  Cristiana Lupi; Riccardo Giannini; Clara Ugolini; Agnese Proietti; Piero Berti; Michele Minuto; Gabriele Materazzi; Rossella Elisei; Massimo Santoro; Paolo Miccoli; Fulvio Basolo
Journal:  J Clin Endocrinol Metab       Date:  2007-09-04       Impact factor: 5.958
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.